Full Prescribing
Information
About APP
About APP
APP Pharmaceuticals, Inc., is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products. The company’s primary focus is centered on the anesthetic/analgesic, anti-infective, critical care and oncology markets. APP offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics throughout North America, and manufactures a comprehensive range of dosage formulations.
Through continuous expansion of our broad portfolio of products, which cover a wide array of therapeutic categories, the company provides ongoing affordable healthcare to millions of people in North America struggling with critical illnesses.
Headquartered in Schaumburg, Illinois, APP has more than 1,800 employees that are united in their commitment to operational and manufacturing excellence in the ultimate effort to provide products that elevate patient care.
APP Pharmaceuticals, Inc., which was acquired by Fresenius Kabi Pharmaceuticals Holding, Inc., on September 10, 2008, is a member of the Fresenius Kabi Group. Fresenius Kabi Pharmaceuticals Holding, Inc., is a wholly owned subsidiary of Fresenius Kabi AG, which is a 100% subsidiary of Fresenius SE.
For more information about APP, click here.
Important Safety Information
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
New Safety Information
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.
Please see Full Prescribing Information at www.naropin-us.com.
®
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
New Safety Information
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.
Please see Full Prescribing Information at www.naropin-us.com.
NAROPIN® and logo are registered trademarks of APP Pharmaceuticals, LLC.
®and APP® are registered trademarks of APP Pharmaceuticals, LLC.
©2010, APP Pharmaceuticals, LLC. All Rights Reserved.